- Home
- GDEN vs GHRS Comparison
GDEN vs GHRS Comparison
Compare GDEN & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDEN
- GHRS
- Stock Information
- Founded
- GDEN 1998
- GHRS 2018
- Country
- GDEN United States
- GHRS Ireland
- Employees
- GDEN N/A
- GHRS N/A
- Industry
- GDEN Services-Misc. Amusement & Recreation
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- GDEN Consumer Discretionary
- GHRS Health Care
- Exchange
- GDEN Nasdaq
- GHRS Nasdaq
- Market Cap
- GDEN 727.9M
- GHRS 811.3M
- IPO Year
- GDEN 1999
- GHRS 2021
- Fundamental
- Price
- GDEN $24.80
- GHRS $14.09
- Analyst Decision
- GDEN Buy
- GHRS Strong Buy
- Analyst Count
- GDEN 7
- GHRS 8
- Target Price
- GDEN $34.86
- GHRS $30.63
- AVG Volume (30 Days)
- GDEN 224.9K
- GHRS 207.5K
- Earning Date
- GDEN 11-06-2025
- GHRS 08-07-2025
- Dividend Yield
- GDEN 4.03%
- GHRS N/A
- EPS Growth
- GDEN N/A
- GHRS N/A
- EPS
- GDEN 0.54
- GHRS N/A
- Revenue
- GDEN $649,900,000.00
- GHRS N/A
- Revenue This Year
- GDEN N/A
- GHRS N/A
- Revenue Next Year
- GDEN $2.29
- GHRS N/A
- P/E Ratio
- GDEN $45.84
- GHRS N/A
- Revenue Growth
- GDEN N/A
- GHRS N/A
- 52 Week Low
- GDEN $22.66
- GHRS $6.00
- 52 Week High
- GDEN $35.49
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- GDEN 40.85
- GHRS 56.97
- Support Level
- GDEN $23.95
- GHRS $13.71
- Resistance Level
- GDEN $25.49
- GHRS $14.42
- Average True Range (ATR)
- GDEN 0.60
- GHRS 0.65
- MACD
- GDEN 0.11
- GHRS 0.19
- Stochastic Oscillator
- GDEN 45.45
- GHRS 77.68
About GDEN Golden Entertainment Inc.
Golden Entertainment Inc is a U.S. based company that focuses on distributed gaming, casino, and resort operations. Its reportable segments are Nevada Casino Resorts, Nevada Locals Casinos, Nevada Taverns, and Distributed Gaming. The majority of the revenue for the company is generated from its Nevada Casino Resorts segment which is comprised of destination casino resort properties offering a variety of food and beverage outlets, entertainment venues, and other amenities.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.